Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Jan 15, 2022; 14(1): 334-347
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.334
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.334
Exosomal content | Sample | Expression | Content identification | Animal model (Yes/No) | Function | Ref. |
HCC | ||||||
Proteins | ||||||
ENO1 | Cancer cells-exosomes, tissue (n = 94) | Up | IHC staining | Y | Promotes HCC growth, metastasis, and further patient deterioration | [57] |
miRNAs | ||||||
miR-125a/b | TAMs-exosomes Tissue (n = 6) | Down | qRT-PCR | N | A possible therapeutic target in HCC | [58] |
miR-150-3p | Fibroblasts-exosomes, tissues (n = 82) | Down | qRT–PCR | N | Abrogate HCC migration and invasiveness | [59] |
miR-32-5p | Bel/5-FU-exosomes, tissue (n = 72) | Up | qRT–PCR | Y | Induce multidrug resistance in HCC | [60] |
miR-320a | Cancer cells-exosomes, tissue (n = 6) | Down | qRT–PCR | Y | Mediates HCC tumor progression | [61] |
miR-3682-3p | Cancer cells-exosomes, tissue (n = 8) | Down | qRT–PCR | Y | Attenuate angiogenesis and provides novel potential targets for liver cancer therapy | [62] |
miR-378b | Cancer cells-exosomes, tissue (n = 105) | Up | qRT–PCR | Y | Enhance HCC cell progression and angiogenesis | [63] |
lncRNAs | ||||||
ASMTL-AS1 | Cancer cells-exosomes, tissues (n = 70) | Up | qRT–PCR | Y | Aggravate the malignancy in residual HCC | [64] |
PCED1B-AS1 | Cancer cells-exosomes, tissues (n = 45) | Up | qRT–PCR | Y | Induce immunosuppression in HCC | [65] |
circRNAs | ||||||
circRNA Cdr1as | Cancer cells-exosomes, tissues (n = 42) | Up | qRT–PCR | Y | Promote the progression of HCC by sponging miR-1270 to upregulate AFP level | [66] |
- Citation: Wei XC, Liu LJ, Zhu F. Exosomes as potential diagnosis and treatment for liver cancer. World J Gastrointest Oncol 2022; 14(1): 334-347
- URL: https://www.wjgnet.com/1948-5204/full/v14/i1/334.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i1.334